Adebrelimab with chemoradiation for esophageal small cell cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of the immunotherapy drug adebrelimab with standard chemotherapy and radiation for people with a rare type of esophageal cancer called small cell carcinoma. The goal is to see if this approach can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with small cell carcinoma of the esophagus that has not spread to distant organs (stages T1-4, N0-3, M0).
- You have not had any prior chemotherapy, radiation, or other systemic treatment for this cancer.
- You are between 18 and 75 years old and in generally good health (able to carry out daily activities).
- Your major organs (heart, lungs, liver, kidneys, bone marrow) are working well enough, as shown by routine blood and lab tests.
- You agree to provide a tumor tissue sample for testing before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called adebrelimab (an immunotherapy) combined with chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery or has come back after surgery. It aims to see if the combination is safe and effective.
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and radiation for people with early-stage esophageal cancer that cannot be surgically removed. It aims to see if this approach can shrink or control the cancer without needing an operation.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy before surgery for esophageal squamous cell carcinoma (a type of throat cancer). The goal is to shrink the tumor and improve outcomes before the surgical removal of the cancer.
This trial tests adding the immunotherapy drug adebrelimab to standard chemotherapy and radiation to see if it works better than chemotherapy alone for people newly diagnosed with extensive-stage small cell lung cancer.
This trial tests a new approach for people with a certain type of esophageal cancer. Instead of surgery right away, you would receive chemotherapy, radiation, and an immunotherapy drug called adebrelimab. After that, doctors will closely watch your cancer to see if it's gone. The goal is to avoid surgery if the treatment works well.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
Hear when a new Esophageal Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.